Skip to main content
SpringerLink
Log in

The role of positron emission tomography within the spectrum of medical imaging

  • Occasional survey
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The aim of the survey is to help to define the role of positron emission tomography (PET) as an investigative procedure, and to identify strategies to perfect PET and in vivo tracer studies in general so that their full potential is realised. Within this context, the sensitivity and specificity of PET are reviewed. The impact of PET through studies of regional cerebral activation based on blood flow measurements is discussed. Emphasis is placed on the role of PET in clinical research and as a means of assessing new therapeutic agents. This latter ability renders PET of much interest to pharmaceutical companies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Artemov D, Bhujwalla ZM, Maxwell RJ, Griffiths, Judson IR, Leach MO, Glickson JD. Pharmacokinetics of the13C labelled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer.Magn Reson Med 195; 34: 338–342.

    Google Scholar 

  2. Bailey DL, Zito F, Gilardi M-C, Savi AR, Fazio F, Jones T. Performance comparison of a state-of-the-art neuro-SPECT scanner and dedicated neuro-PET scanner.Eur J Nucl Med 1994; 21: 381–387.

    Google Scholar 

  3. Sedvall G, Farde L. Chemical brain anatomy in schizophrenia.Lancet 1995; 346: 743–749.

    Google Scholar 

  4. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, Mckenna P, Chua SE, Schnorr L, Jones T, Frackowiak RSJ. A functional neuroanatomy of hallucinations in schizophrenia.Nature 1995; 378: 176–179.

    Google Scholar 

  5. Bartenstein PA, Duncan JS, Prevett MC, Cunningham VJ, Fish DR, Jones AKP, Luthra SK, Sawle GV, Brooks DJ. Investigation of the opioid system in absence seizures with positron emission tomography.J Neurol Neurosurg Psychiatry 1993; 56: 1295–1302.

    Google Scholar 

  6. Jones AKP, Vincent LQ, Cunningham V, Ha-Kawa SK, Fujiwara T, Luthra SK, Jones T. Changes in central opioid receptor binding in relation to inflammation and pain in patients with rheumatoid arthritis.Br J Rheumatol 1994; 33: 909–919.

    Google Scholar 

  7. Tilsley DWO, Harte RJA, Jones T, Brady F, Luthra SK, Brown G, Price PM. New techniques in the pharmacokinetic analysis of cancer drugs. IV. Positron emission tomography.Cancer Surv 1993; 17: 425–442.

    Google Scholar 

  8. Ritter JM, Jones T. PET: a symposium highlighting its clinical and pharmacological potential.Trends Pharmacol Sci 1995; 16: 117–119.

    Google Scholar 

  9. Comar D. Pet for drug development and evaluation. Developments in nuclear medicine, vol 26. Dordrecht: Kluwer Academic Publishers; 1995.

    Google Scholar 

  10. Leiden JM. Gene therapy — promise, pitfalls, and prognosis.N Engl J Med 1995; 333: 871–872.

    Google Scholar 

  11. Nickles RJ, Nunn AD, Stone CK, Christian BT. Technetium-94m teboroxime: synthesis, dosimetry and initial PET imaging studies.J Nucl Med 1993; 34: 1058.

    Google Scholar 

  12. Rösch F, Novgorodov AF, Qaim SM. Thermochromatographic separation of94mTc from enriched molybdenum targets and its large scale production for nuclear medical application.Radiochim Acta 1993; 62: 115–121.

    Google Scholar 

  13. Christian BT, Nickles RJ, Stone CK, Mulnix TL, Clark J. Improving the radionuclidic purity of94mTc for PET imaging.Appl Radiat Isot 1995; 46: 69–73.

    Google Scholar 

  14. Zweit J, Luthra SK, Brady F, Carnochan P, Ott RJ, Jones T. Iodine-120, a new positron emitting radionuclide for PET radiopharmaceuticals. Proceedings of Eleventh International Symposium on Radiopharmaceutical Chemistry, Vancouver, Canada. 1995: 823–825.

  15. Flower MA, Al-Saadi A, Harmer CL, McCready R, Ott RJ. Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy.Eur J Nucl Med 1994; 21: 531–536.

    Google Scholar 

  16. Wilson CB, Snook DE, Dhokia B, Taylor CVJ, Watson IA, Lammerstsma AA, Lambrecht R, Waxman J, Jones T, Epenetos AA. Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and124iodine in patients with breast cancer.Int J Cancer 1991; 47: 344–347.

    Google Scholar 

  17. Pentlow KS, Graham MC, Lambrecht RM, Cheung N-KV, Larson SM. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy.Med Phys 1991; 18: 357–366.

    Google Scholar 

  18. Hawkins PN, Tyrrell P, Jones T, Rossor MN, Roques P, Myers M, Lambrecht R, Richardson S, Gudmundsson G, Pepys MB. Metabolic and scintigraphic studies with radiolabelled serum amyloid P component in amyloidosis: applications to cerebral deposits and Alzheimer disease with positron emission tomography.Bull Clin Neurosci 1991; 56: 178–190.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cyclotron Unit, Medical Research Council Clinical Sciences Centre, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK

    Terry Jones

Authors
  1. Terry Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, T. The role of positron emission tomography within the spectrum of medical imaging. Eur J Nucl Med 23, 207–211 (1996). https://doi.org/10.1007/BF01731847

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01731847

Key words

Search

Navigation